Drugs / AZD3199
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01222442 | Nov 2010 → Feb 2011 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00772759 | Oct 2008 → Feb 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00713271 | Aug → Nov 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01348139 | May 2011 → Feb 2012 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00929708 | Jun 2009 → Mar 2010 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00736489 | Aug → Dec 2008 | asthma, obstructive lung disease | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD3199 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00713271 ↗ |
| Action | Activate | “Beta-2 adrenergic receptor agonist” CHEMBL3545103 ↗1“AZD3199 (a B2-agonist)” NCT00713271 ↗ |
| Route | Inhaled | “Given Once Daily as Inhaled Formulation Via Turbuhaler” NCT00713271 ↗ |
| Target | ADRB2 | “Beta-2 adrenergic receptor agonist” CHEMBL3545103 ↗ |